Paxillin is positively correlated with the clinicopathological factors of colorectal cancer, and knockdown of Paxillin improves sensitivity to cetuximab in colorectal cancer cells

Author：            

Publisher： Spandidos Publications

E-ISSN： 1791-2431|35|1|409-417

ISSN： 1021-335X

Source： Oncology Reports, Vol.35, Iss.1, 2016-01, pp. : 409-417

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer

By Chen Dong-Liang   Wang De-Shen   Wu Wen-Jing   Zeng Zhao-Lei   Luo Hui-Yan   Qiu Miao-Zhen   Ren Chao   Zhang Dong-Sheng   Wang Zhi-Qiang   Wang Feng-Hua   Li Yu-Hong   Kang Tie-Bang   Xu Rui-Hua  

Carcinogenesis, Vol. 34, Iss. 4, 2013-04 ,pp. : 803-811

Oxford University Press

Access to resources Recommend Favorite

Cetuximab in the treatment of colorectal cancer

By Ciardiello Fortunato   De Vita Ferdinando   Orditura Michele   Comunale Daniela   Galizia Gennaro  

Future Oncology, Vol. 1, Iss. 2, 2005-04 ,pp. : 173-181

Future Medicine

Access to resources Recommend Favorite

Cetuximab: from biology to the care of colorectal cancer patients

By Vincenzi Bruno   Santini Daniele   Tonini Giuseppe  

Future Oncology, Vol. 3, Iss. 5, 2007-10 ,pp. : 497-499

Future Medicine

Access to resources Recommend Favorite

Emerging Role of Cetuximab in the Treatment of Colorectal Cancer

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 7, Iss. 2, 2012-05 ,pp. : 233-247

Bentham Science Publishers

Access to resources Recommend Favorite

Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival

By                                

Molecular and Clinical Oncology, Vol. 3, Iss. 5, 2015-01 ,pp. : 1053-1057

Science Publishers

Access to resources Recommend Favorite